E.ON SE Sponsored ADR (Germany) (OTCMKTS:EONGY) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of E.ON SE Sponsored ADR (Germany) (OTCMKTS:EONGY) from a sell rating to a hold rating in a research report released on Tuesday, Zacks.com reports.

According to Zacks, “E.ON AG is the world’s largest investor-owned energy service provider with operations in the following businesses: energy, chemicals, real estate, oil, telecommunications, distribution/logistics, aluminum and silicon wafers. “

EONGY has been the subject of a number of other reports. Kepler Capital Markets restated a hold rating on shares of E.ON SE Sponsored ADR (Germany) in a report on Tuesday. Macquarie started coverage on shares of E.ON SE Sponsored ADR (Germany) in a report on Monday, June 17th. They set a neutral rating for the company. Goldman Sachs Group cut shares of E.ON SE Sponsored ADR (Germany) from a neutral rating to a sell rating in a report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. cut shares of E.ON SE Sponsored ADR (Germany) from a neutral rating to an underweight rating in a report on Wednesday, July 31st. Three research analysts have rated the stock with a sell rating and seven have given a hold rating to the company. E.ON SE Sponsored ADR (Germany) has a consensus rating of Hold and an average price target of $12.00.

EONGY stock opened at $9.03 on Tuesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.50 and a quick ratio of 1.47. E.ON SE Sponsored ADR has a 52-week low of $9.01 and a 52-week high of $11.35. The company has a 50-day moving average of $10.34 and a two-hundred day moving average of $10.75. The stock has a market capitalization of $20.02 billion, a price-to-earnings ratio of 10.87, a price-to-earnings-growth ratio of 3.24 and a beta of 0.85.

E.ON SE Sponsored ADR (Germany) (OTCMKTS:EONGY) last released its quarterly earnings results on Monday, May 13th. The utilities provider reported $0.34 earnings per share (EPS) for the quarter. E.ON SE Sponsored ADR (Germany) had a net margin of 3.07% and a return on equity of 12.25%. The company had revenue of $10.18 billion during the quarter. Equities analysts expect that E.ON SE Sponsored ADR will post 0.77 EPS for the current fiscal year.

About E.ON SE Sponsored ADR (Germany)

E.ON SE operates as an energy company in Germany, the United Kingdom, Romania, Hungary, the Czech Republic, Sweden, the United States, Poland, Italy, Denmark, and internationally. It operates through three segments: Energy Networks, Customer Solutions, and Renewables. The company provides power and gas distribution networks and related services; and distributes energy solutions to residential customers, small and medium sized enterprises, large commercial and industrial customers, and public entities.

Read More: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on E.ON SE Sponsored ADR (Germany) (EONGY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for E.ON SE Sponsored ADR (Germany) (OTCMKTS:EONGY)

Receive News & Ratings for E.ON SE Sponsored ADR (Germany) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for E.ON SE Sponsored ADR (Germany) and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

E.ON SE Sponsored ADR   Upgraded at Zacks Investment Research
E.ON SE Sponsored ADR Upgraded at Zacks Investment Research
MITIE GRP PLC/ADR  Downgraded by Zacks Investment Research
MITIE GRP PLC/ADR Downgraded by Zacks Investment Research
Hammerson  Upgraded by Royal Bank of Canada to “Outperform”
Hammerson Upgraded by Royal Bank of Canada to “Outperform”
National Express Group  Lifted to “Hold” at Zacks Investment Research
National Express Group Lifted to “Hold” at Zacks Investment Research
Axovant Gene Therapies  Upgraded to “Outperform” by Robert W. Baird
Axovant Gene Therapies Upgraded to “Outperform” by Robert W. Baird
HC Wainwright Downgrades Melinta Therapeutics  to Neutral
HC Wainwright Downgrades Melinta Therapeutics to Neutral


 
© 2006-2019 Zolmax.